Goldman Sachs Group Inc. lifted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 10.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 935,685 shares of the medical instruments supplier’s stock after purchasing an additional 86,022 shares during the period. Goldman Sachs Group Inc. owned about 1.26% of West Pharmaceutical Services worth $88,441,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Acrospire Investment Management LLC bought a new position in West Pharmaceutical Services during the second quarter valued at about $113,000. Citigroup Inc. grew its position in shares of West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 765 shares during the period. Harfst & Associates Inc. bought a new position in shares of West Pharmaceutical Services during the 1st quarter valued at approximately $186,000. Wolverine Trading LLC bought a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $200,000. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of West Pharmaceutical Services by 1.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 40 shares during the last quarter. Institutional investors own 90.57% of the company’s stock.

Several research firms recently commented on WST. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Friday, June 23rd. Stephens started coverage on West Pharmaceutical Services in a research note on Tuesday. They set an “equal weight” rating and a $99.00 price target for the company. BidaskClub lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Jefferies Group LLC raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $96.00 to $115.00 in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. West Pharmaceutical Services presently has a consensus rating of “Hold” and a consensus target price of $107.33.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at http://www.mareainformativa.com/west-pharmaceutical-services-inc-wst-shares-bought-by-goldman-sachs-group-inc/115805/.

West Pharmaceutical Services, Inc. (NYSE:WST) traded down 0.67% during trading on Wednesday, hitting $93.99. The stock had a trading volume of 26,063 shares. The company has a market cap of $6.96 billion, a price-to-earnings ratio of 40.34 and a beta of 1.12. West Pharmaceutical Services, Inc. has a 52-week low of $70.17 and a 52-week high of $99.91. The company has a 50-day moving average price of $90.36 and a 200-day moving average price of $90.56.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company had revenue of $397.60 million for the quarter, compared to the consensus estimate of $406.00 million. During the same period in the previous year, the business earned $0.59 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post $2.68 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be paid a $0.14 dividend. The ex-dividend date of this dividend is Tuesday, October 17th. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. West Pharmaceutical Services’s dividend payout ratio (DPR) is 22.22%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.